



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## N-Acetyl-S-(2-hydroxyethyl)-L-cysteine-d<sub>4</sub> dicyclohexylamine

<b>Cat. No.:</b>	HY-132805S
<b>CAS No.:</b>	1331894-57-5
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>32</sub> D <sub>4</sub> N <sub>2</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	392.59
<b>Target:</b>	Isotope-Labeled Compounds
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (254.72 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.5472 mL	12.7359 mL	25.4719 mL	
5 mM	0.5094 mL	2.5472 mL	5.0944 mL	
10 mM	0.2547 mL	1.2736 mL	2.5472 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

N-Acetyl-S-(2-hydroxyethyl)-L-cysteine-d<sub>4</sub> (dicyclohexylamine) is the deuterium labeled N-Acetyl-S-(2-hydroxyethyl)-L-cysteine dicyclohexylamine salt<sup>[1]</sup>.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA